GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background & Aims Direct-acting anti-viral agents suppress hepatitis B virus (HBV) load but must be given lifelong. Stimulation of the innate immune system could increase its ability to control the virus and have long lasting effects, after a finite regimen. We investigated the effects of immune activation with GS-9620—a potent and selective orally active small molecule agonist of Toll-Like Receptor (TLR)7—in chimpanzees with chronic HBV infection. Methods GS-9620 was administered to chimpanzees every other day (3 times each week) for 4 weeks at 1 mg/kg and, after a 1 week rest, for 4 weeks at 2 mg/kg. We measured viral load in plasma and liver samples, the pharmacokinetics of GS-9620, and the following pharmacodynamics parameters: interferon (IFN)-stimulated gene expression, cytokine and chemokine levels, lymphocyte and natural killer cell activation, and viral antigen expression. Clinical pathology parameters were monitored to determine the safety and tolerability of GS-9620. Results Short-term oral administration of GS-9620 provided long-term suppression of serum and liver HBV DNA. The mean maximum reduction of viral DNA was 2.2 logs, which occurred within 1 week of the end of GS-9620 administration; reductions of greater than 1 log persisted for months. Serum levels of HB surface antigen and HB e antigen, and numbers of HBV antigen-positive hepatocytes, were reduced as hepatocyte apoptosis increased. GS-9620 administration induced production of IFN-α and other cytokines and chemokines, and activated ISGs, natural killer cells, and lymphocyte subsets. Conclusions The small molecule GS-9620 activates TLR-7 signaling in immune cells of chimpanzees to induce clearance of HBV-infected cells. This reagent might be developed for treatment of patients with chronic HBV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Immunology of hepatitis B virus and hepatitis C virus infection
Rehermann, B., & Nascimbeni, M. (2005) · Nature Reviews Immunology · doi:10.1038/nri1573 · Cited by 1,627
Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection
Guidotti, L. G., Rochford, R., Chung, J., Shapiro, M., Purcell, R., & Chisari, F. V. (1999) · Science · doi:10.1126/science.284.5415.825 · Cited by 1,223
Thimme, R., Wieland, S., Steiger, C., Ghrayeb, J., Reimann, K. A., Purcell, R. H., & Chisari, F. V. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.68-76.2003 · Cited by 979
Werle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905 · cited 1×
“These results are in stark contrast to those observed in patients during therapy with nucleos(t)ide analogues which can reduce serum HBV DNA by 4 logs or greater, yet no significant reduction occurs in serum HBsAg or HBcAg positive hepatocytes over 48 weeks of therapy.(20) Unfortunately, the number of HBV core antigen…”
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 1×
“therapeutic target for cancer, viral infections, and other diseases.(12-15) GS-9620 is a potent, orally active TLR-7 agonist with selectivity for induction of IFN-α over pro-inflammatory cytokines.”
Nucleic acid recognition by the innate immune system
Barbalat, R., Ewald, S. E., Mouchess, M. L., & Barton, G. M. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101340 · Cited by 577 · cited 4×
“The low rate of HBsAg loss and seroconversion with current therapies illustrate the need for new approaches to induce a protective anti-viral immune response and durable cure in patients with chronic HBV. Toll-like receptor-7 (TLR-7) is a pathogen recognition receptor predominantly expressed in lysosomal/endosomal com…”
InfluentialThree-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
Heathcote, E. J., Marcellin, P., Buti, M., Gane, E., De Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.011 · Cited by 462
Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics
Kearney, B. P., Flaherty, J. F., & Shah, J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443090-00003 · Cited by 456
Cited by
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
Nassal, M. (2015) · Gut · doi:10.1136/gutjnl-2015-309809 · Cited by 899
Therapeutic strategies for hepatitis B virus infection: towards a cure
Fanning, G. C., Zoulim, F., Hou, J., & Bertoletti, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0037-0 · Cited by 557
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Nguyen, M. H., Wong, G., Gane, E., Kao, J.-H., & Dusheiko, G. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-19 · Cited by 554
Cornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 366
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.008 · Cited by 344
Present and future therapies of hepatitis B: From discovery to cure
Liang, T. J., Block, T. M., McMahon, B. J., Ghany, M. G., Urban, S., Guo, J., Locarnini, S., Zoulim, F., Chang, K., & Lok, A. S. (2015) · Hepatology · doi:10.1002/hep.28025 · Cited by 317
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Hepatology · doi:10.1002/hep.29323 · Cited by 303
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Wong, G. L. H., Gane, E., & Lok, A. S. F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.024 · Cited by 272
Savva, A., & Roger, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00387 · Cited by 261
Gish, R. G., Given, B. D., Lai, C.-L., Locarnini, S. A., Lau, J. Y. N., Lewis, D. L., & Schluep, T. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.008 · Cited by 259
Menne, S., Tumas, D. B., Liu, K. H., Thampi, L., AlDeghaither, D., Baldwin, B. H., Bellezza, C. A., Cote, P. J., Zheng, J., Halcomb, R., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.026 · Cited by 208
“Conclusions: The data demonstrate that short duration, finite treatment with the oral TLR7 agonist GS-9620 can induce a sustained antiviral response in the woodchuck model of CHB, and support investigation of this compound as a therapeutic approach to attain a functional cure in CHB patients.”
InfluentialSelf-citationJanssen, H. L. A., Brunetto, M. R., Kim, Y. J., Ferrari, C., Massetto, B., Nguyen, A.-H., Joshi, A., Woo, J., Lau, A. H., Gaggar, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.027 · Cited by 203
Ferrari, C. (2015) · Liver International · doi:10.1111/liv.12749 · Cited by 196
“In particular, TLR9 agonists have been shown to induce efficient CTL expansion in mice (75), TLR7 agonists to induce intrahepatic IFN-a production in HBV infected chimpanzees (76) through their capacity to stimulate plasmocitoid dendritic cells and TLR8 agonists to induce a strong intrahepatic production of IFN-a in a…”
BackgroundHepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver
Suslov, A., Boldanova, T., Wang, X., Wieland, S., & Heim, M. H. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.034 · Cited by 169
The Critical Role of Nonhuman Primates in Medical Research - White Paper
Friedman, H., Haigwood, N., Ator, N., Newsome, W., Allan, J. S., Golos, T. G., Kordower, J. H., Shade, R. E., Goldberg, M. E., Bailey, M. R., et al. (2017) · Pathogens and Immunity · doi:10.20411/pai.v2i3.186 · Cited by 108
Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35
Metadata
- Authors
- Lanford, R. E., Guerra, B., Chavez, D., Giavedoni, L., Hodara, V. L., Brasky, K. M., Fosdick, A., Frey, C. R., Zheng, J., Wolfgang, G., Halcomb, R. L., & Tumas, D. B.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 144
- Issue
- 7
- Pages
- 1508-1517.e10
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2027555120
- Cited by
- 377
- References
- 28
- FWCI
- 26.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.